

Contents lists available at ScienceDirect

Leukemia Research Reports



journal homepage: www.elsevier.com/locate/lrr

Improving patient understanding and outcomes in myelodysplastic syndromes - An animated patient guide to MDS with visual formats of learning

David A. Sallman^a, Rafael Bejar^{b,*}, Guillermo Montalban-Bravo^c, Sandra E. Kurtin^d, Alan F. List^e, Guillermo Garcia-Manero^c, Stephen D. Nimer^f, Casey L. O'Connell^g, Dale Schaar^h, Janice Butchkoⁱ, Tracey Iracaⁱ, Stephanie Searle^j

^b Division of Hematology and Oncology, MDS Center of Excellence, University of California, San Diego La Jolla, CA, United States

- ^c Department of Leukemia, University of Texas MD Anderson Cancer Center Houston, TX, United States
- ^d University of Arizona Cancer Center, University of Arizona Tucson, AZ, United States

e Precision BioSciences Durham, NC, United States

^f Department of Medicine, Biochemistry & Molecular Biology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center Miami, FL, United States

^g Jane Anne Nohl Division of Hematology, University of Southern California Los Angeles, CA, United States

^h Rutgers Cancer Institute of New Jersey New Brunswick, NJ, United States

ⁱ MDS Foundation, NJ, United States

^j Mechanisms in Medicine Inc., Toronto, ON, Canada

ARTICLE INFO

Keywords: Health literacy Health outcomes Myelodysplastic syndromes Patient education Visual formats of learning

ABSTRACT

Objectives: Patient education resources that address barriers to health literacy to improve understanding and outcomes in myelodysplastic syndromes (MDS) are limited. The aim of this study was to evaluate the impact and outcomes benefits of *An Animated Patient's Guide to Myelodysplastic Syndromes (MDS)* cancer educational modules (which includes the 'You and MDS' website and YouTube hosted resources) related to MDS education, awareness, understanding and health outcomes.

Methods: This was a retrospective study of learner feedback, metrics, and utilization data from July 2018 to August 2021. We evaluated audience reach (number of visit sessions, unique visitors, page views) and calculated top views by media type (animation, expert video, patient video, and slide show) and top retention videos from the modules. We also assessed the educational impact and utilization through learner feedback surveys.

Results: During the study period, 'You and MDS' had 233,743 views worldwide of which 104,214 were unique visitors and 78,161 (or 76% unique visitors) were from the United States. Of these, 61% were patients; 29% family members or caregivers; 5% were healthcare providers and 5% represented other groups. Most popular topics viewed among the animations were "Understanding Myelodysplastic Syndromes (MDS)" (40,219 views), "Managing and Treating MDS" (19,240 views), "Understanding Erythropoiesis" (17,564 views.) The most popular expert videos viewed were "What is iron overload, and how it is treated?" (20,310 views), "How serious a cancer is MDS? What is the prognosis for MDS?" (8,327 views), "What is MDS?" (3,157 views). Of participants who completed the online feedback survey, \geq 95% reported improved knowledge gains and commitments to change.

Conclusions: MDS patients using 'You and MDS - An Animated Patient's Guide to MDS' and its visual formats of learning represented a wide U.S. and global learner audience. This MDS educational resource had a significant impact on improved understanding among patients, families, and caregivers. Continued efforts should be made to provide patient-effective resources that address health literacy, improve patient understanding, and address educational needs that respond to the concerns of patients to achieve better quality of life and improved health outcomes in MDS.

* Corresponding author.

E-mail address: rabejar@health.ucsd.edu (R. Bejar).

https://doi.org/10.1016/j.lrr.2022.100328

Received 29 December 2021; Received in revised form 7 May 2022; Accepted 22 May 2022 Available online 25 May 2022

2213-0489/© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

^a Department of Malignant Hematology, Moffitt Cancer Center Tampa, FL, United States

Myelodysplastic syndromes (MDS) represent a heterogeneous group of hematologic malignancies that are not well understood, and are characterized by ineffective hematopoiesis, variable cytopenias, and risk of progression to acute myeloid leukemia [1]. MDS is a significant cause of cancer morbidity and mortality in the United States, with an estimated 10,000 new diagnoses each year [2]. The prevalence of MDS is estimated to be between 60,000 – 170,000 patients in the US [3] The Revised International Prognostic Symptom Score (IPSS-R) median survival for low-risk patients may extend to 8.8 years; however, in high-risk patients the median survival may be a mere 0.8 years [4]. Advanced age is the predominate risk factor, with a median age of diagnosis of 71-76 years [5].

As survival rates for MDS patients are poor, understanding mechanisms of early events in disease development and new approaches for early detection and management are necessary for better outcomes [6]. In an Internet-based survey among 358 patients with MDS, 55% of patients did not know their IPSS score; 42% were unaware of their blast percentage; 28% were unaware of their cytogenetics and 16% of patients felt treatment would be curative [7]. Patients with high-risk disease were more likely to think their therapy would be curative than those with lower-risk disease. Patients with MDS have a limited understanding of their disease characteristics, prognosis, and treatment goals. Little information is available regarding how aware MDS patients are of their disease severity, prognosis, and treatment outcomes [8].

One of the key factors that can negatively impact patients' health outcomes is low health literacy [9-13]. Prior studies have linked lower levels of health literacy to poorer health-related quality of life [14] and a lower likelihood of receiving chemotherapy (cancer patients) [15].

In our study, we evaluated the impact of Myelodysplastic Syndromes Foundation's (MDSF's) 'You and MDS: An Animated Patient's Guide to MDS' education modules using visual formats of learning to improve patient understanding and address educational needs over a period of 3 years [16,17]. We monitored an audience of patients, families, and caregivers to determine audience learning activities, feedback, and interactions. We assessed the efficacy of 'You and MDS' and its role in addressing knowledge gaps and understanding by reducing learning barriers for patients to make informed decisions and partner with their health care providers to attain optimal health outcomes.

1. Materials and methods

1.1. Study design and participants

This is a retrospective study of the 'You and MDS' website and YouTube audience metrics for learner activities related to MDS patient education and allied learner lay audiences, conducted from July 2018 through August 2021; a period of 38 months. With the 'You and MDS' website launch, we utilized a series of outreach efforts using social media communications (YouTube, Facebook, Twitter, Instagram) to address awareness and access which included MDS Foundation's existing patient and family audiences, and *de novo* audiences in the United States and globally. Future efforts will continue expansionary opportunities to use social media assets to promote this resource to a wide audience of learners. Although participants visiting the 'You and MDS' modules on the website and YouTube channels are largely comprised of patients, and their families and caregivers, a significant number of users of the English-language resource are health care professionals validating the benefits of this resource in MDS patient clinics and care centers.

1.2. Content development and access

The educational content for the 'You and MDS' resources were developed by MDS Foundation's multidisciplinary scientific advisors consisting of hematologists, oncologists, stem cell transplant specialists, nurse practitioners and health care providers at MDS Centers of Excellence. Online content is easily accessible, highly visual in nature, and



Fig. 1. You and MDS website (https://www.YouandMDS.com).

interactive in presentation (Fig. 1). The education materials were designed to serve a lay audience with a grade 6 to 8 health literacy level (as assessed by literacy online evaluation tools). Each module was created to be succinct, practical, informative, evidence-based, patient-

Animations

- Understanding Myelodysplastic Syndromes (MDS)
- Diagnosis of Myelodysplastic Syndromes (MDS)
- Managing and Treating MDS
- Blood and Marrow Transplant in MDS
- Understanding MDS-related Anemia
- · Managing and Treating MDS-related Anemia
- Understanding Erythropoiesis

Expert Videos

Understanding Myelodysplastic Syndromes

- What is MDS?
- What causes MDS?
- What are the symptoms of MDS?
- What are the risk factors for MDS?
- Can MDS be prevented?
- Is MDS hereditary? Does genetics play a role?
- What are the types of MDS?
- How is MDS classified?
- How serious a cancer is MDS? What is the prognosis for MDS?

Diagnosis of MDS

- How is MDS diagnosed?
- What is involved in screening for MDS?
- What is genetic testing for MDS?
- · What are the clinical features and symptoms of MDS?
- What are the overlap syndromes that have features of MDS?
- What is the prognostic classification of MDS?

Management and Treatment of MDS

- What are the treatment options for MDS?
- How is lower-risk MDS treated?
- How is higher-risk MDS treated?
- What is supportive care for MDS?
- Are vitamin supplements beneficial for MDS treatment?
- What are erythropoietin-stimulating agents (ESAs)?
- What is cytotoxic chemotherapy and when is it used for MDS?
- What is lenalidomide and when is it used for MDS?
- What are hypomethylating agents and when are they used for MDS?
- How long will MDS treatment be given?
- What is immunosuppressive therapy and when is it used for MDS?
- What other options are there if first-line MDS treatment doesn't work?

Blood and Marrow Transplantation in MDS

- What is a blood and marrow transplant (BMT)?
- Who can be a blood and marrow transplant donor?
- How is a blood and marrow transplant done? What should I expect?
- What is Graft-Versus-Host Disease (GVHD) and why does it happen?
- How effective is blood and marrow transplantation (BMT)?
- Is blood and marrow transplantation (BMT) safe?

- **Understanding MDS-related Anemia**
- What is MDS-related anemia? What causes it?
- What is a complete blood count? How does it show if I have anemia?
- What are the symptoms of MDS-related anemia?
- What makes people with MDS more likely to have anemia?
- What happens in MDS-related anemia over time?
- What's the prognosis for MDS-related anemia? How is prognosis determined?
- Which questions should I ask my doctor about my MDS-related anemia?
- · How is MDS-related anemia diagnosed? • How is MDS-related anemia screened and monitored?
- Which other conditions have symptoms similar to MDS-related anemia?
- If I have MDS-related anemia, what should I watch out for in daily life?
- Which specific diagnosis questions should I ask my doctor about my MDS? · How does acute myeloid leukemia (AML) relate to MDS?
- Why is it important to understand the causes of unexplained anemia?
- Managing and Treating MDS-related Anemia
- What are the treatment options for MDS-related anemia?
- What are the goals of treatment for MDS-related anemia?
- · How is higher-risk MDS-related anemia treated?
- What is "refractory anemia" and "primary anemia"? Are these terms still in use?
- When do people with MDS-related anemia need blood transfusions?
- · How often could I need a blood transfusion for MDS-related anemia?
- Are blood transfusions safe? Are there risks?
- What is iron overload, and how it is treated?
- Can my bone marrow return to normal and produce its own red blood cells?
- What new treatments are in development for MDS-related anemia?
- Are there clinical trials for MDS-related anemia? What does the future hold?
- What treatment questions should I ask my doctor about my MDS?
- When is a blood and marrow transplant (stem cell transplant) used for MDS-related anemia?

Fig. 2. Overview of educational Animations and Expert Video content from You and MDS program.

centric and aligned with the chosen learning objectives. The MDS educational curriculum is comprehensive in content, with opportunities to expand learning content in the future (Fig. 2).

The 'You and MDS' content contains animations, expert videos, and patient experience videos, slide shows and infographics. Each of the animations and videos were developed to be viewed within a 3 to 7 minutes timeframe. The MDS education modules can be accessed directly from the MDS Foundation's website at www.https://www.md s-foundation.org or directly through an online resource, www.youa ndmds.com or a YouTube channel at https://www.youtube.com/c /YouandMDS/featured. The list of accessible animations, expert videos, slide shows, infographics, and patient experience videos is illustrated in Tables 1 and 2. The website provides learner interactivity; a learner 'pop-quiz' allows users to self-test their knowledge skills and a

homepage invitation prompts users to provide comments via an optional feedback survey.

1.3. User metrics measurement and statistical analysis

Data were reported as frequencies, and proportions and mean $(\pm SD)$, where appropriate. We evaluated audience reach, demographics, and metrics such as the number of visit sessions, number of unique visitors, page views, duration of page views, and duration of video views for the 'You and MDS' website and the 'You and MDS' YouTube channel. We also calculated top views, top views by media type (animation, expert video, patient experience video, storyboard slide show, infographic) and top retention videos overall for the website and YouTube channel. Finally, we assessed the educational impact of the 'You and MDS" program from

Table 1

Top 5 Animations and Top 10 Expert Videos by Frequency.

Video Type	Video Title	YouTube	APP	Total
Animations	Understanding Myelodysplastic	21,887	18,332	40,219
	Managing and Treating MDS	11 243	7 007	10.240
	Understanding Emithropoiosis	16 526	1 020	17 564
	Diagnosis of Music duer lockie	10,520	6 1 2 6	10,607
		4,551	0,130	10,087
	Syndromes (MDS)	0.460	0.400	6.004
	Blood and Marrow	3,468	3,430	6,904
_	Transplantation in MDS			
Expert	What is iron overload, and how it	20,228	82	20,310
videos	is treated?			
	How serious a cancer is MDS?	5,630	2697	8,327
	What is the prognosis for MDS?			
	What is MDS?	187	2970	3,157
	What are the symptoms of MDS?	597	1723	2,320
	What causes MDS?	287	1841	2,128
	Are vitamin supplements	370	1521	1,891
	beneficial for MDS treatment?			
	What are the types of MDS?	358	1204	1,562
	What are erythropoietin-	970	571	1,541
	stimulating agents (ESAs)?			
	What are the risk factors for MDS?	93	1245	1.338
	How is lower risk MDS treated?	160	1079	1,239

Table 2

Top 5 Animations and Top 10 Expert Videos by Highest Retention Viewed.

Video Type	Video Title	Average Percentage Viewed
Animations	Managing and Treating MDS	58.9
	Understanding Myelodysplastic Syndromes (MDS)	56.7
	Diagnosis of Myelodysplastic Syndromes (MDS)	56.3
	Understanding MDS-related Anemia	54.5
	Understanding Erythropoiesis	53.9
Expert	What are the treatment options for MDS?	83.5
videos	What are the risk factors for MDS?	82.9
	Are vitamin supplements beneficial for MDS treatment?	82.6
	Which other conditions have symptoms similar to MDS-related anemia?	81.7
	How is MDS diagnosed?	80.9
	What is involved in screening for MDS?	80.9
	Can my bone marrow return to normal and produce its own red blood cells?	80.8
	What new treatments are in development for MDS-related anemia?	80.5
	What are the symptoms of MDS-related anemia?	80.3
	How is MDS-related anemia screened and monitored?	80.1

Retention determined by the percentage of the total video length viewed.

the metrics data; the user utilization of learning resources; accessing data of areas of high and low interest; and monitoring and collecting specific learner feedback survey data.

2. Results

2.1. Participant characteristics

During the study period, the 'You and MDS' website (Fig. 1) and YouTube channel had 233,743 total views ('You and MDS' website = 134,863; YouTube = 98,880). Overall, the educational content was accessed by 104,214 unique visitors from 141 countries. Most of the unique visitors to the website (76% or 79,203) were from the United States while 25,038 unique visitors were from other countries; namely

Table 3

Direct Comments from Patients,	Caregivers and	Website	Visitors in Respons	e to
the Educational Information Red	reived.			

Visitor	Direct Comment
туре	
Patient	I had two stem cell transplants - very good and clear explanation of
	MDS.
Patient	I was diagnosed 24 years ago, have been treated weekly for 15 years;
	and I was a PhD Organic/Biochemist specialist in chemical
	mechanisms in living systems. I enjoyed this, though, since it is a good
D	simple explanation, I can send to people who ask about it.
Patient	linfo provided enhances and validates what my hematologist has
Detiont	Thenk you. This information has been your helpful. My blood counts
Patient	have been decreasing for the pact several years and have leveled off I
	am now on a 12 month check. Bre MDS. Have an excellent doctor and
	team.
Patient	This was very informative as I was just diagnosed within the week.
Patient	Very grateful for the video and all the information provided. I have
	learned a lot more here than at the Dr's office.
Patient	My hematologist considers me to be Very Low to Low risk. This week I
	have started Decitabine treatments for anemia because my HBG is
	below 7.0. My hematologist has been very informative and has
	informed me exactly what your animation has shown. I have
	forwarded this animation to my siblings and family so that they will
	have a better understanding of my MDS.
Patient	Will pass this on to my family and nurse.
Patient	I can't find the list of questions to ask my doctor.
Patient	Really great videos. Thank you! Especially the animated ones at the
	top. And the patient perspectives helpful.
Patient	The above questions are not relevant, only because I already talked to
Dationt	If you have not been able to find much about how one physically feels with
raticiit	MDS besides blood tests and level of tiredness what are the
	symptoms to look for?
Other	Excellent videos
Other	Excellent informative easy to understand!
Other	Very informative website.
Other	Thank you, this site is very helpful.
Caregiver	Thank you for making these videos. My mom was just diagnosed with
	the del(5q) version.
Caregiver	Thank you for the videos. Very helpful! I think this will also help my
	92-year-old mother.
Caregiver	Stem cell transplant is scheduled So far, it seems my husband's MDS
	is right on track with what I have seen on this website.

United Kingdom (4%); Canada (4%); China (3%); Australia (2%) and other countries (11%).

Of the 1,850 respondents who provided feedback, more than half of participant responses (61%) identified as MDS patients; the remainder were family or caregivers (29%), health care providers (5%), and other (5%).

2.2. Animation, expert videos, and patient videos

Table 1 lists the most popular topics for the animation and videos. "Understanding Myelodysplastic Syndromes (MDS)" (40,219 views), "Managing and Treating MDS" (19,240 views), "Understanding Erythropoiesis" (17,564 views), "Diagnosis of Myelodysplastic Syndromes (MDS)" (10,687 views), "Blood and Marrow Transplantation in MDS" (6,904 views) were the top animations viewed, respectively.

The most popular expert videos viewed by the participants were "What is iron overload, and how it is treated?" (20,310 views), "How serious a cancer is MDS? What is the prognosis for MDS?" (8,327 views), "What is MDS?" (3,157 views), "What are the symptoms of MDS?" (2,320 views), and "What causes MDS?" (2,128 views) (Table 1).

2.3. Viewer retention for animations and videos

Table 2 lists the top 5 animations and top 10 videos by viewer



Fig. 3. Patients who experienced improved outcomes.

retention (as determined by the percentage of the total video length viewed). On average, 70.1% of each video's content was viewed.

2.4. Direct comments from patients, caregivers and visitors

Table 3 lists a sample of direct quotes of patients, caregivers and website visitors showing different or similar perspectives on the educational information received. This feedback was based on "Short Survey Question # 4. Do you have any other comments or unanswered questions?" and "Long Survey Question # 12. Other questions I have about MDS?"

2.5. Participant knowledge and commitment to change

Among the 1,850 participants who completed the online feedback survey, approximately 95% reported that they had learned new MDS information. 86% learned new diagnosis information, 87% learned new treatment options, and 84% learned new blood and marrow transplant information for MDS. Most participants (96%) expressed a commitment to change, in terms of using the information to better manage their MDS, and indicated their intention to engage with their doctor in discussions (Fig. 3).

3. Discussion

During the 3-year study period, the MDS Foundation's 'You and MDS – An Animated Patient's Guide to MDS' education modules garnered 233,743 views and approximately 104,214 unique participants. The most popular topic among the animations was "Understanding Myelodysplastic Syndromes (MDS)" and the most popular expert video viewed was "What is iron overload, and how it is treated?". Participants who completed the online feedback survey reported knowledge gains and commitment to change by engaging with their physician or implementing a newly learned self-management action.

Myelodysplastic syndromes cause substantial morbidity, mortality, and costs. While the efforts to improve MDS outcomes are being pursued in areas related to early diagnosis, surveillance, and advances in treatments, reliable educational resources specific to MDS patient needs and understanding of disease are limited. Current cancer patient education resources and content is predominantly text based [18–26] and most often written at literacy levels above the comprehension level of lay persons, even though National Institutes of Health and the American Medical Association recommend a 5th grade to 8th grade target comprehension level for patient education materials [27,28].

The Myelodysplastic Syndromes Foundation's 'You and MDS - An Animated Patient's Guide to MDS' uses visual formats of learning to address patient barriers to health literacy and provides accessible, easyto-follow, evidence-based resources. Multidisciplinary expert author faculty guide evidence-based content development of the website and You Tube resources. Educational content is simple to understand; brief animations with narration focusing on frequently asked questions and key disease concepts are easily understood. Short video segments of experts answering commonly asked questions complement learning tools; videos of patients sharing their MDS disease experiences and downloadable slide shows, and infographics add to the content covered by animations. The content of the education modules aligns with the health literacy literature on the effectiveness of visual aids and video formats in patient education [29]. The feedback survey on self-reported gains in learning, competence, and intention to change also align with Moore and colleagues [30], which is consistent with level 4 outcomes for continuing medical education. This unique format of learning permits feedback from learners through voluntary self-evaluation tools and encourages learners to indicate benefits in knowledge acquisition; learners indicate their intent to discuss an intervention with their hematology/oncology provider and the interactive format elicits and reports on improved learner understanding. Education content helps learners make informed choices and share in decisions with their health care providers regarding MDS management.

Some of the strengths of our study assessed over a period of 3 years include wide reach of this program (US and global audience), use of a multidisciplinary expert faculty from MDS Centers of Excellence in the development of content, addressing health literacy impediments, and improving understanding related to MDS patient needs. Patients are capable of participating in shared decisions through educational modules, which promote patient satisfaction with their health care experience [31,32]. Educational animations and content are continuously being added for the English and Spanish programs, while other language programs are feasible in the future to benefit global MDS communities.

The limitation of this study includes its retrospective design and a relatively small percentage of users (\sim 1.8%) who took part in the optional feedback survey. Our study is reliant on self-reported data, with no opportunity to independently confirm participants' reports of their

disease history and treatment. Another limitation is the potential for learner response bias in the population who elected to complete online self-evaluation and feedback. Moreover, You Tube learner audiences are unlikely to provide feedback, without visiting the 'You and MDS' website. Although the 'You and MDS' resources received approximately 233,743 views worldwide, few (n = 1,850) participated in the feedback survey. This is because the feedback survey was optional (no monetary compensation is provided). Furthermore, additional requests for feedback would potentially deter voluntary responses and the goal was to facilitate a broad response. In the future an opportunity will be evaluated to compare the results from incentivized responses with results from the current audience of patients, families and caregivers utilizing this online resource. It is anticipated that introducing such an incentive will improve feedback and provide greater insights related to representation of learner knowledge translation and highlight unmet needs. Collection of learner response data will guide future content development and address learning improvements for MDS patients. The program also lacked a formal pre-survey/post-survey assessment. Because of the nature of the feedback survey, we were limited in gathering indepth learner data, however future goals are to improve the quality of information from heterogeneous learner audiences.

In conclusion, An Animated Patient's Guide to Myelodysplastic Syndromes: You and MDS, that uses visual formats of learning, demonstrates wide reach, and has vast potential to improve understanding and benefit health outcomes by informing MDS patients, families, and caregivers.

Future areas of focus for this MDS patient resource will be based directly on feedback from patients and families in order to provide education on new therapies, clinical trials, diagnostic tools, and developments in MDS transplant interventions and ultimately improve patient outcomes. Continued efforts should be made to provide patient resources that address health literacy barriers, increase disease understanding, improve health outcomes and quality of life.

Declaration of Competing Interest

No conflict of interest in relation to this manuscript. No funding was requested or received for the development of this manuscript. *You and MDS: An Animated Patient's Guide to Myelodysplastic Syndromes* is supported by unrestricted education grants from Acceleron Pharma, Bristol-Myers Squibb, Celgene Corporation, Jazz Pharmaceuticals, Novartis, and Takeda Oncology. Mechanisms in Medicine, the developers of this resource, declare no conflict of interest in the development of the program.

References

- [1] S.D. Nimer, Myelodysplastic syndromes, Blood 111 (10) (2008) 4841-4851.
- [2] Myelodysplastic syndromes. MDS statistics. https://www.cancer.net/cancer -types/myelodysplastic-syndromes-mds/statistics.
- [3] Leukemia and Lymphoma Society. https://www.lls.org/research/myelodysplasticsyndrome-mds-research-funded-lls.
- [4] American Cancer Society. Survival statistics for myelodysplastic syndromes. https://www.cancer.org/cancer/myelodysplastic-syndrome/detection-diagnosis-staging/survival.html.
- [5] Leukemia and Lymphoma Society. https://www.lls.org/research/myelodysplasticsyndrome-mds-research-funded-lls.
- [6] M.A. Sekeres, J.P. Maciejewski, A.F. List, D.P Steensma, et al., Perceptions of disease state, treatment outcomes, and prognosis among patients with

myelodysplastic syndromes: results from an internet-based survey, The Oncologist 16 (6) (2011) 904–911, 08 April.

- [7] M.A. Sekeres, J.P. Maciejewski, A.F. List, D.P Steensma, et al., Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey, The Oncologist 16 (6) (2011) 904–911, 08 April.
- [8] Sekeres M.A., Maciejewski J.P., List A.F. et al. Perceptions of disease state, treatment outcomes, and prognosis among patients with myelodysplastic syndromes: results from an internet-based survey. 08 April 2011.
- [9] ND Berkman, SL Sheridan, KE Donahue, et al., Low health literacy and health outcomes: an updated systematic review, Ann Intern Med 155 (2011) 97–107.
- [10] H Levy, A. Janke, Health literacy and access to care, J Health Commun 21 (suppl 1) (2016) 43–50.
- [11] Hersh L, Salzman B, Snyderman D. Health literacy in primary care practice. Am Fam Physician. 2015; 92:118–124.
- [12] BD. Weiss, Health literacy and patient safety: help patients understand. Manual for Clinicians, 2nd ed., American Medical Association, Chicago, IL, 2007.
- [13] Institute of Medicine (US) Committee on Health Literacy, What is health literacy? in: L Nielsen-Bohlman, AM Panzer, DA Kindig (Eds.), Health Literacy: A Prescription to End Confusion National Academies Press (US), Washington, DC, 2004.
- [14] JL Halverson, AP Martinez-Donate, M Palta, et al., Health literacy and healthrelated quality of life among a population-based sample of cancer patients, J Health Commun 20 (2015) 1320–1329.
- [15] EL Busch, C Martin, DA DeWalt, et al., Functional health literacy, chemotherapy decisions, and outcomes among a colorectal cancer cohort, Cancer Control 22 (2015) 95–101.
- [16] The Myelodysplastic Syndromes Foundation [website home page]. 2021. Available at: https://www.mds-foundation.org/.
- [17] Animated Patients Guide to MDS [website home page]. 2021. Available at www. YouAndMDS.com.
- [18] NCCN Guidelines for Patients, Myelodysplastic Syndromes. National Comprehensive Cancer Network, NCCN Foundation, 2021. https://www.nccn.org/ patients/guidelines/content/PDF/mds-patient.pdf.
- [19] A Storino, M Castillo-Angeles, AA Watkins, et al., Assessing the accuracy and readability of online health information for patients with pancreatic cancer, JAMA Surg 151 (2016) 831–837.
- [20] AV Prabhu, DR Hansberry, N Agarwal, et al., Radiation oncology and online patient education materials: deviating from NIH and AMA recommendations, Int J Radiat Oncol Biol Phys 96 (2016) 521–528.
- [21] AV Prabhu, AL Donovan, T Crihalmeanu, et al., Radiology online patient education materials provided by major university hospitals: do they conform to NIH and AMA guidelines? Curr Probl Diagn Radiol 47 (2018) 75–79.
- [22] AV Prabhu, T Crihalmeanu, DR Hansberry, et al., Online palliative care and oncology patient education resources through Google: do they meet national health literacy recommendations? Pract Radiat Oncol 7 (2017) 306–310.
- [23] DR Hansberry, N Agarwal, ES John, et al., Evaluation of internet-based patient education materials from internal medicine subspecialty organizations: will patients understand them? Intern Emerg Med 12 (2017) 535–543.
- [24] KD Weiss, CR Vargas, et al., Readability analysis of online resources related to lung cancer, J Surg Res 206 (2016) 90–97.
- [25] DR Hansberry, SR Patel, P Agarwal, et al., A quantitative readability analysis of patient education resources from gastroenterology society websites, Int J Colorectal Dis 32 (2017) 917–920.
- [26] AV Prabhu, C Kim, T Crihalmeanu, et al., An online readability analysis of pathology-related patient education articles: an opportunity for pathologists to educate patients, Hum Pathol 65 (2017) 15–20.
- [27] BD. Weiss, Health Literacy and Patient Safety: Help Patients Understand. Manual for Clinicians, 2nd ed., American Medical Association, Chicago, IL, 2007.
- [28] NIH. Clear Communication. Clear and Simple. Available: https://www.nih.gov/ins titutes-nih/nih-office-director/office-communications-public-liaison/clear-comm unication/clear-simple. 2007.
- [29] Nienkamp M. Visual learning tools overcome health literacy. [PSQH e-Newsletter]. July–August 2006. Available at: https://www.psqh.com/julaug06/visual.html . Accessed February 1, 2021.
- [30] DE Moore Jr, JS Green, HA Gallis, Achieving desired results and improved outcomes: integrating planning and assessment throughout learning activities, J Contin Educ Health Prof 29 (2009) 1–15.
- [31] HL Kane, MT Halpern, LB Squiers, et al., Implementing and evaluating shared decision making in oncology practice, CA Cancer J Clin 64 (2014) 377–388.
- [32] SJ Katz, S. Hawley, The value of sharing treatment decision making with patients: expecting too much? JAMA 310 (2013) 1559–1560.